Navigation Links
China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009
Date:12/11/2009

Expense

Despite the ongoing marketing effort, management continued to tightly monitor sales and marketing expense. Sales and marketing expense as a percentage of net revenue declined from 15.1% last year to 14.8% for the quarter ended September 30, 2009. Total sales and marketing expense for the quarter ended September 30, 2009 was RMB9.5 million (US$1.4 million), an increase of 28.3% from RMB7.4 million for the same period last year.

General and Administrative Expense

To cope with the rising demand and better serve our existing markets, new storage facilities were constructed which boosted total capacity more than six fold, and as a result, in conjunction with work force expansion, total administrative expense for the quarter ended September 30, 2009 increased to RMB12.7 million (US$1.9 million) compared to RMB5.1 million for the same period last year.

Operating Income

Operating income for the quarter ended September 30, 2009 was RMB24.1 million (US$3.5 million) compared to RMB24.8 million for the same period last year because the increase in net revenue was offset by the increase in administrative expense. Operating margin for the quarter ended September 30, 2009 was 37.8%.

Earnings Before Interest, Taxes, Depreciation and Amortization ("non-GAAP EBITDA")

Non-GAAP EBITDA for the quarter ended September 30, 2009 was RMB28.9 million (US$4.2 million), a slight increase of 8.9% year-over-year, translating into a non-GAAP EBITDA margin of 45.3%.

Net Income Attributable To China Cord Blood Corporation Shareholders

Net income attributable to shareholders for the quarter ended September 30, 2009 increased to RMB17.6 million (US$2.6 million), up from RMB5.8 million for the same period of 2008. Net income attributable to shareholders margin for the quarter ended September 30, 2009 was 27.6%, up from 11.8%. Basic earnings per sha
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009
2. Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China
3. ESC to give talks on diabetes in 3 cities in China
4. China Medical Technologies Reports Second Fiscal Quarter Financial Results
5. China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009
6. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
7. Novartis to Acquire Majority Stake in Hard to Treat Diseases (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million
8. Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin
9. HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China
10. China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores
11. China Medical Technologies to Announce Unaudited Financial Results for the Second Fiscal Quarter Ended September 30, 2009 on November 19, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... foodies everywhere have long recognized ginger as a great ... sweet and savory dishes; now, a study from researchers ... root also may have properties that help asthma patients ... will be presented at the ATS 2013 International Conference. ... the bronchial tubes that carry air into and out ...
(Date:5/19/2013)... People in Minnesota have a great option ... offering its 28 Day Fat Loss Formula. The best ... of their own home. The product sells for $135 dollars ... be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is ... now, but after using the 28 Day Fat Loss Formula ...
(Date:5/19/2013)... 19, 2013 Today, Zane Benefits, ... business health insurance . Zane Benefits, which provides ... health benefits, is the leader in health care ... reimbursement arrangements . , According to Zane Benefits’ ... intrinsically know the value of small business health ...
(Date:5/19/2013)... These molecular diagnostics market reports provide ... Italy, Germany and France:,     Major ... as well as key economic, regulatory, demographic, social ... the next five years. ,     An extensive ... formats, detection methodologies, trends in testing automation and ...
(Date:5/19/2013)... Americans live closer to their dogs than ... Medical Association (AVMA) U.S. Pet Ownership and Demographics Sourcebook, ... dog a member of the family, up from the ... years earlier. , According to the American Pet Products ... dedicated to pets has increased every year without interruption, ...
Breaking Medicine News(10 mins):Health News:Ginger compounds may be effective in treating asthma symptoms 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3
... May 20 - XanGo, LLC, the mangosteen beverage category ... icon, former presidential advisor, philanthropist and motivational speaker Doug ... brings to XanGo deep experience in direct selling, having ... the past 30 years. He previously served as special ...
... WILL BE SOLD ON iTUNES TO RAISE FUNDS FOR ... Will Be Donated To D.C.-Based Accelerate Brain Cancer CureLOS ... the seventh season of "American Idol," David Cook returns ... Wednesday night to perform "Permanent," -- a song he ...
... WINNIPEG, May 20 /PRNewswire/ - The Children,s Hospital ... on its newly commissioned RIVA System (Robotic Intravenous ... syringes and bags from Intelligent Hospital Systems (IH ... The Children,s Hospital of Philadelphia was rated first ...
... RALEIGH, N.C. , May 20 ... healthcare grade televisions and on-demand patient and staff interactive ... on-demand video education and entertainment system into ... expanded and renovated its facility, adding two new floors ...
... May 1st, 2009 in TEDA Tianjin, ChinaTEDA Tianjin, China, ... contract manufacturer of API,s and intermediates, and Drug Products ... opening if its high potency Active Pharmaceutical Ingredient (API) ... This dedicated facility is sited at Asymchem,s TEDA Tianjin ...
... and Healthcare Industry Leaders to Measure Impact of Patient ... A group of prominent healthcare leaders, clinicians, researchers ... Institute for Interactive Patient Care (IIPC). ... for the importance of patient engagement as a means ...
Cached Medicine News:Health News:Direct Selling Icon, Former Presidential Advisor Doug Wead Joins XanGo 2Health News:Direct Selling Icon, Former Presidential Advisor Doug Wead Joins XanGo 3Health News:David Cook to Perform 'Permanent' on the American Idol Season Finale Tonight 2Health News:TeleHealth Services Chosen by HCA to Install Interactive Patient Education System in Timpanogos Regional Hospital 2Health News:TeleHealth Services Chosen by HCA to Install Interactive Patient Education System in Timpanogos Regional Hospital 3Health News:TeleHealth Services Chosen by HCA to Install Interactive Patient Education System in Timpanogos Regional Hospital 4Health News:Asymchem Announces Opening of High Potency API and Drug Product Facility 2Health News:Institute for Interactive Patient Care Launched 2Health News:Institute for Interactive Patient Care Launched 3Health News:Institute for Interactive Patient Care Launched 4
(Date:5/17/2013)... , May 17, 2013  Boehringer Ingelheim will ... disease at the American Thoracic Society International Conference ... , May 17 – 22. Data ... for the treatment of chronic obstructive pulmonary disease ... well as investigational compounds for asthma, idiopathic pulmonary ...
(Date:5/17/2013)... 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 inhibitor ... both dose groups. The primary endpoint assessed the proportion ... with data reported in previous trials, the most common ... results will be presented at an upcoming medical congress. ...
(Date:5/17/2013)... NATICK, Mass. , May 17, 2013  Boston ... to participate at the annual EuroPCR Scientific Program May ... "We are pleased to present a particularly rich and ... Keith Dawkins , M.D., global chief ... several trials will be presented, including the NG PROMUS ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
... the advantages of the IPL Quantum DL and ... and other deeper vascular lesions. This cost-effective system ... alone device or as an upgrade to the ... range of conditions including: Leg veins ...
... powerful, versatile, and innovative aesthetic treatments to ... Light and Laser System.,With StarLux you attach ... so theres no need to buy ... choose among Laser, Intense Pulsed Light, and ...
... (Western Blot): The assay uses immortalized human ... surface. The cells are fixed to the ... uninfected T-cells are provided as a control. ... HIV- I antibodies comes in contact with ...
... say the most efficient,aspiration is ... movement of the,cannula tip. Rigorous ... ARC-H II Reciprocating Cannula,assures that ... is,restricted to a longitudinal axis ...
Medicine Products: